Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
App on AR-Smartglasses for improved autonomy and mobility of visual impaired persons (Retiplus)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Spain
Call: Open Disruptive Innovation Scheme (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2018-02-01
End date: 2018-06-30
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Plusindes is a private company born with the main mission of providing visually impaired people with solutions to assist their very complicated daily living. Visual impairment, also known Low Vision, is a condition caused by eye disease in which the ability to see is decreased to a degree that causes problems not fixable by usual means, such as eyeglasses, contact lenses, medicines or surgery. With low vision it is hard or impossible to do many of normal daily tasks such as driving, reading, socializing or walking. It is therefore a disabling condition that affects very negatively the quality of life of affected people, who lose their autonomy and thus become highly frustrated and depressed in most cases. Furthermore, visual impairments have considerable economic costs both directly due to the cost of treatment and indirectly due to decreased ability to work. Retiplus will offer low vision patients a usable and versatile solution for improved mobility, accessibility and autonomy that will not imply them suffering from the social awkwardness of wearing a signpost in their heads to advertise their disability. Retiplus is a patented technology to compensate vision impaired troubles based on wearable augmented reality (AR) smartglasses which basic mode of action is exploiting the residual vision of visually impaired people to assist them in daily activities. It is calculated that there are more than 285 million people who were visually impaired of which 246 million have low vision and 39 million are totally blind. This unfortunate picture of the reality is in fact the validation of the Retiplus investment opportunity.

Keywords: augmented reality,low vision
Making SENSE of the Water value chain with Copernicus Earth Observation, models and in-situ data (WaterSENSE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Space
Theme: Enabling European research in support of international space partnerships
Action type: Research and Innovation actions
Countries involved: Australia,Germany,Netherlands,Netherlands,Netherlands,Portugal
Call: International Cooperation Copernicus – Designing EO downstream applications with international partners (H2020-SPACE-2019, 2019)
Start date: 2020-01-01
End date: 2024-06-30
Duration (months): 54.0
Total project cost (EUR): 1999174.86
EU funding (EUR): 1999174.8599999999
Participants: 10
Project status: SIGNED

Shortages of freshwater will be one of the most pressing problems in feeding the world this century. To optimize use of available water it is important to distribute it wisely over the various competing interests, in particular agriculture, which is responsible for 70% of all freshwater use. Irrigation is currently often unsustainable, while groundwater reserves are becoming depleted and many places in the world are suffering water shortages. Action is therefore required now to use space and in-situ monitoring systems, to create a better sense of water availability and optimise use across the planet. WaterSENSE will provide water-availability and mapping services for any place in the world at different time and space resolutions, based on integrated Copernicus data, hydrological models and local data. The results of these services will be open access so as to further develop value-adding services. WaterSENSE itself will deliver the essential value-added service of monitoring compliance of local water use against water rights and regulations (‘water auditing’). The first application will be in the multi-climate Murray-Darling Basin in Australia, followed by validation in South Africa and the Netherlands. Consortium partners already provide water-availability and water-auditing services in the latter two countries. Novel research in the project will develop scalable information services, based on advanced big-data processing algorithms, to determine variables such as evapotranspiration, irrigation water use, rainfall and soil moisture, as well as machine learning to allow automatic data processing and reduce uncertainty in the hydrological variables determined. DIAS services for data provision, as well as cloud hosting and processing of computational services, will be developed and implemented. Existing successful partnership models will be refined to ensure service providers in the water value chain achieve healthy business development.
Molecular Basis of Toxoplasma gondii Encystation and Persistence (ToxoPersist)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Immunity, Infection and Immunotherapy
Panel description: The immune system, related disorders and their mechanisms, biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases, innovative immunological tools and approaches, including therapies
Countries involved: Switzerland
Call: ERC Advanced Grant (ERC-2015-AdG, 2015)
Start date: 2016-10-01
End date: 2022-09-30
Duration (months): 72.0
Total project cost (EUR): 2297606.0
EU funding (EUR): 2297606.0
Participants: 1
Project status: CLOSED

Toxoplasma gondii is the most successful obligate intracellular parasites infecting virtually all warm-blooded animals. A infection initiates with the dissemination of the fast-replicating tachyzoites. At the onset of the immune response tachyzoites convert into slow-growing bradyzoites that form cysts in the central nervous system and in striated and heart muscles. Encystation ensures life-long persistence and poses a significant threat of reactivation during immunosuppression and can lead to encephalitis and severe clinical manifestations. Despite the importance of encystation for pathogenesis and transmission, our insight into how T. gondii defies the immune responses to take up permanent residence in the immunocompetent hosts is rudimentary. We propose to determine the molecular mechanisms governing cyst wall formation and parasite adaption to encystation. We will capitalize on the increased sensitivity of -omics approaches, the power of the CRISPR/Cas9 genome editing, the high-resolution microscopy, and on the ex-vivo tissue examination by MALDI imaging mass spectrometry and NanoSIMS technologies.The specific objectives are to: 1. Identify the components of the Cyst Wall (CW), Parasitophorous Vacuole (PV) and PMV Membrane (PVM) of the cyst 2. Determine the parasite factors responsible for CW formation and maturation via targeted and unbiased approaches 3. Define the metabolic network of parasite that is able to initiate encystation and ensure persistence 4. Measure subversion of host metabolic functions by parasite effectors during encystation and persistence We anticipate fundamental discoveries on i) the regulatory and trafficking circuits that govern CW formation as a biological barrier during encystation ii) metabolic adaptation and subversion of host cellular functions during encystation. Ultimately, understanding parasite strategies and versatilities that ensures its parasitism in immunocompetent hosts and bottlenecks as new targets for intervention.

Keywords: protein trafficking,host parasite interface,persistence,chronic infection
Novel catheter to reduce Urinary Tract Infections (UTIs) (T-CONTROL)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-08-01
End date: 2018-11-30
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

T-Control is an innovative indwelling urinary catheter. Urinary Catheters (UC) are one of the most frequently used medical devices on the market. They are used during medical interventions and treatment, as well as incontinence or urine retention in case of spinal cord injury, prostate hypertrophy, weak muscle, and many other conditions. There are several unmet needs related to currently used catheters. They cause a sharp decline of quality of life of the patients, are linked to frequent emergency visits and increase substentially the risk of infection both for patients and health care professionals. There are about 1,3 million cases in EU, causing 1,8 bn EUR direct cost and more than 14,000 deaths. T-Control is addressing all the previously mentioned problems thanks to its novel design and a special hydrophobic membrane material, with patent approval both in EU and US, developed after 4 years of R&D. T-Control will reduce additional days of hospitalization (leading to €1.14B savings in EU alone), but also guarantee the safety of health workers and decreasing continence related waste (sheets, gloves, diapers, catheters, bags…) representing around 29% of medical waste in non-acute hospitals. Rethink Medical SL develops new medical solutions, mainly linked to nursing. It raised the interest of 16 stakeholders on the market (Letters of Support). The feasibility study (SME Phase 1) shall address a financial plan, foreseeing all the costs and investments associated with commercializing our custom-made UC and the expected revenues. The study will also aim at assessing other important aspects such as IPR management, determine the best investment route for the growth stage, and conclude the best channels to reach customers and how we can best explain our difference from competition (prescribers, events, hospitals…). All these activities will lead to the ratification of a detailed business plan that will pave the way towards an effective market introduction.

Keywords: urology,indwelling catheter,urinary track infection,emergency assistance,occupational risk,medical device,validation,regulation,certification
A unique and innovative cleanliness test bench that allows to increase test efficiency and reduce costs for cleanliness assessment of hydraulic, automotive and aeronautic components and systems (CLEAN CABINET)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Italy
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2018)
Start date: 2018-09-01
End date: 2021-10-31
Duration (months): 38.0
Total project cost (EUR): 2501412.5
EU funding (EUR): 1750988.75
Participants: 1
Project status: CLOSED

Most of the wear and fatigue problems suffered by hydraulic systems are caused by solid contaminants, usually generated during the manufacturing process of the components. These particles have a big impact in the reliability and life expectancy of the hydraulic systems, as well as in their efficiency and in their overall energy consumption. The state-of-the-art solutions for cleanliness evaluation need, at least, a contaminant extraction system, a drying oven and a microscope, all of it installed in a clean-room laboratory and operated by skilled technicians. Apart from complex, this is scarcely effective and very costly. OilSafe is an Italian SME funded in 1998. CLEAN CABINET is our disruptive solution for cleanliness testing. It integrates all the previously mentioned processes in a single and fully automated device, from the extraction to the image analysis. Our solution doesn’t need a laboratory, can be readily integrated in manufacturing lines and no skilled operators are needed. It is more efficient and is fully compliant with ISO16232. Moreover, the results are obtained much faster and the tests result, at least, four times cheaper. Its use will have a big impact in the quality of the hydraulic systems because it enables to perform more tests at lower cost. Initially, the target sectors will be machinery (construction, agriculture, etc.) automotive and aeronautic, although applications can be encountered in many sectors. A first prototype is already working with very good results. The goals of the project are to integrate the image analysis module and some additional features in a new prototype before launching it to the market and to develop the commercial network needed to sell it, first in Italy and then in the rest of Europe. The project will last 2 years with an estimated budget of 2,5M€. We expect to sell more than 500 units during the fifth year after the completion of the project, for a ROI of 7.8, and we foresee to create 18 new jobs in OilSafe

Keywords: tribology,wear and fatigue,contamination,maintenance,quality control,materials,hydraulics systems,cleanliness,image analysis
Low-temperature anaerobic digestion treatment of low-strength wastewaters (Lt-AD)

Framework: Horizon 2020 — Societal Challenges
Programme: Climate action, environment,  resource efficiency and raw materials
Action type: SME instrument
Countries involved: Ireland
Call: Boosting the potential of small businesses for eco-innovation and a sustainable supply of raw materials (H2020-SMEINST-1-2014, 2014)
Start date: 2014-11-01
End date: 2015-04-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

NVP Energy presents the first to market, high-rate anaerobic digestion (AD) technology that successfully treats low strength wastewater (WW) at ambient temperatures (< 20°C). The low-temperature (Lt-AD) process provides a novel solution to Food and Drinks industrial sectors producing large WW volumes requiring treatment. The sector of interest is milk treatment and processing, a growing market producing over 367 billion litres annually; WW is typically treated using conventional aerobic processes resulting in high sludge yields, requiring a large footprint on-site and a heavy reliance on fossil fuels. Lt-AD produces negligible sludge volumes, has a compact design, requires no heat input or biogas recirculation, and produces effluent of urban wastewater directive (UWWD) standard (< 125 mg/L COD) without post-aeration. A typical dairy processing plant producing 5,000 m3 WW per day can save 97% on operational costs by replacing aerobic treatment with Lt-AD, and generate annual biogas revenue of €616,266. The technology's low temperature operation allows for 100% of the biogas produced being available for reuse or resale. The process also has a high impact on environmental savings through reduced greenhouse gas (GHG) emissions, lowered thermal energy and fossil fuels requirements. This feasibility study will allow NVP Energy to build relationships with potential users, assess EU market opportunities, and determine resources required to deliver a full WW treatment solution in terms of technical, legal, environmental, marketing, sales, manufacturing or service capabilities. The outcomes will be the securing of a demonstrator industrial site, achieving an in-depth understanding of the EU market, building concrete relationships with collaborators and ultimately producing an all-embracing business plan. Phase 2 delivery of Lt-AD as a full-scale treatment solution for low strength WW producers will be critical to delivering this technology throughout Europe and beyond.

Keywords: waste water,food and drink,effluent,chemical oxygen demand,suspended solids,receiving waters,reactor,ambient temperature,anaerobic digestion,tightening restrictions,release standards
Evolution of the social brain: How social complexity affects individual cognition in ants (BrainiAnts)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: France,United States
Call: Marie Skłodowska-Curie Individual Fellowships (IF-GF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-08-01
End date: 2018-12-31
Duration (months): 36.0
Total project cost (EUR): 246668.4
EU funding (EUR): 246668.4
Participants: 2
Project status: CLOSED

This project aims to answer a significant open question in evolutionary neurobiology: how social complexity shapes the brain structure, its associated metabolic costs, and the behavioural capability of individual members of a society. The Social Brain Hypothesis proposes that the complexity of living in group influences encephalization in vertebrates, but this theory has not been critically tested in invertebrate species. Social insects such as ants have miniaturized brains that nevertheless support highly coordinated collective behaviour and striking individual cognitive abilities. This collective behaviour produces an “externalized” distributed processing of information that may reduce energetic expenses in individual brains. We propose to address this question through the study of brain metabolic costs of ant foragers under different conditions of sociality. We will examine the effect of distributed information processing (such as the use of pheromones trails to coordinate group activity) on individual cognitive abilities (such as learning) and the energetic costs of specialized brain compartments that underlie behaviour. Our interdisciplinary methodology will combine techniques applied to the study of collective animal behaviour (individual tracking in collective choice and foraging experiments) and neurobiology (immunohistochemistry and neuroanatomical scaling, cytochrome oxidase staining and learning assays) in sister clades of ants that show strong differences in social complexity and thus the relative roles of individual workers and cooperative groups. This novel and integrated approach will allow us to analyze the evolutionary relationship between social complexity and brain evolution.

Keywords: collective behaviour,social insects,ants,foraging,pheromone trails,social brain hypothesis,immediate early genes,cytochrome oxydase,videotracking,learning
Integrated Platform for the European Research Infrastructure ON Cultural Heritage (IPERION CH)

Framework: Horizon 2020 — Excellent Science
Programme: Research Infrastructures
Theme: Research infrastructures
Destination: Integrating activities and infrastructures
Action type: Research and Innovation actions
Countries involved: Germany,Italy,Italy,Germany,Spain,Italy,Germany,Italy,Hungary,Poland,Belgium,Greece,Greece,Hungary,France,France,France,United States,Netherlands,Denmark,United Kingdom,United Kingdom,Portugal
Call: Integrating and opening existing national and regional research infrastructures of European interest (H2020-INFRAIA-2014-2015, 2014)
Start date: 2015-05-01
End date: 2019-10-31
Duration (months): 54.0
Total project cost (EUR): 8157487.73
EU funding (EUR): 7994987.73
Participants: 29
Project status: CLOSED

IPERION CH aims to establish the unique pan-European research infrastructure in Heritage Science by integrating national world-class facilities at research centres, universities and museums. The cross-disciplinary consortium of 23 partners (from 12 Member States and the US) offers access to instruments, methodologies and data for advancing knowledge and innovation in the conservation and restoration of cultural heritage. Fourth in a line of successful projects (CHARISMA-FP7, Eu-ARTECH-FP6 and LabS-TECH network-FP5), IPERION CH widens trans-national access by adding new providers with new expertise and instruments to the three existing complementary platforms ARCHLAB, FIXLAB and MOLAB. The quality of access services will be improved through joint research activities focused on development of new advanced diagnostic techniques and (with DARIAH ERIC) tools for storing and sharing scientific cultural heritage data. Networking activities will (a) promote innovation through technology transfer and dynamic involvement of SMEs; (b) improve access procedures by setting up a coordinated and integrated approach for harmonising and enhancing interoperability among the facilities; (c) identify future scientific challenges, best practices and protocols for measurements; (d) optimise the use of digital tools in Heritage Science. To advance the international role of EU cultural heritage research, IPERION CH will generate social and cultural innovation by training a new generation of researchers and professionals and by worldwide dissemination and communication to diverse audiences. To ensure long-term sustainability, the advanced community of IPERION CH will work towards inclusion in the new ESFRI Roadmap and constitution of a RI with its own EU legal entity (e.g. ERIC). Synergies with national and local bodies, and with managing authorities in charge of ESIF, will expand the scope and impact of IPERION CH in terms of competitiveness, innovation, growth and jobs in ERA.

Keywords: heritage science
Clinical validation of Laser Optoacoustic Ultrasonic 3D Imaging System Assembly for breast cancer detection and characterization through endogenous biomarkers. (LOUISA-3D)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Italy
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-1-2014, 2014)
Start date: 2015-05-01
End date: 2015-10-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Breast cancer (BC) is the most common cancer and the first cause of cancer-related deaths in European women. Laser Optoacoustic Ultrasonic 3D Imaging System Assembly (LOUISA-3D) combines optoacoustic functional information from endogenous biomarkers (hemoglobin content and blood oxygen saturation) with high-resolution anatomical images of ultrasound tomography, without the need for ionizing radiation or exogenous contrast media. The objective of LOUISA-3D is to overcome the main limitations of current imaging methods, by validating and introducing to the EU market a novel multi-modality diagnostic device for BC, based on coregistered full view 3D optoacoustic and ultrasonic technology. LOUISA-3D will be a highly effective, safe and affordable imaging method for BC detection, characterization, and evaluation of the effect of neoadjuvant therapy (NAT). Two clinical trials will validate LOUISA-3D. Trial 1 will measure detection rate, recall rate, sensitivity, and positive predictive value of LOUISA-3D as a screening test in a selected female population at increased risk for BC, as compared to standard digital mammography. Trial 2 will assess the LOUISA-3D endogenous biomarkers capability of measuring the NAT effect in the treatment of locally advanced BCs, as compared to contrast-enhanced magnetic resonance imaging. During this feasibility study, an international scientific committee will deliver both trial protocols, and a management board will release a work and financial plan for the trials and a business plan for the production and commercialization of LOUISA-3D, complete market analysis, cost analysis and financial plan. The applying company, Bios, commercializes medical laser systems worldwide. Once validated and CE medical marked, LOUISA-3D will be manufactured and commercialized in EU, representing an important opportunity for Bios to enter the medical imaging market and enable its significant growth.

Keywords: breast cancer,optoacoustic